A novel vaccine that targets inflamed brain cells associated with Alzheimer’s disease may hold the key to potentially preventing or modifying the course of the disease, according to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions 2023.
Verve raises $148M via public stock offering, private placement with Eli Lilly (corrected)
After releasing the first-ever results of an in vivo base editing therapy in humans, Verve Therapeutics has priced a public offering of 12.5 million shares
November 30, 2023